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NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER
First-Generation Epidermal Growth Factor Receptor
Inhibitors in Non-small Cell Lung Cancer: Clinical Impact
of the Epidermal Growth Factor Receptor Fluorescence
In Situ Hybridization Assay
Fred R. Hirsch, MD, PhD,*† Rafal Dziadziuszko, MD, PhD,*‡ Marileila Varella-Garcia, PhD,*
Wilbur A. Franklin, MD,† David R. Gandara, MD,§ and Paul A. Bunn, Jr, MD*
Epidermal growth factor receptor (EGFR) inhibitors have been
proven to improve survival in advanced non-small cell lung cancer
patients, even after failure of previous chemotherapy. However, how
to identify the patients, who will benefit from this treatment, is still
not known. Clinical and demographic factors, i.e., females, never-
smokers, patients with Asian ethnicity, or histology of adenocarci-
noma, seem all to be favorable factors for clinical outcome, but not
sufficient for patient selection. Increased EGFR gene copy number
detected by fluorescence in situ hybridization has consistently been
shown in several retrospective studies to be a good predictive
“marker,” especially for EGFR tyrosine kinase inhibitors. Neverthe-
less, most of the data obtained so far are retrospective, and prospec-
tive validation is ongoing. The current review summarizes the
clinical data based on the first generation EGFR inhibitors and
discusses future strategies for exploring the role of EGFR fluores-
cence in situ hybridization as a selection marker for EGFR inhibitor
therapy in non-small cell lung cancer.
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Epidermal growth factor receptor (EGFR) inhibitors haveproven effective in some patients with advanced non-
small cell lung cancer (NSCLC) previously treated and pro-
gressed on chemotherapy.1 Most data are published on the
EGFR tyrosine kinase inhibitors (TKIs) gefitinib, and erlo-
tinib. Objective response rates in phase II studies with ge-
fitinib and erlotinib are 10 to 18% in western populations and
up to 27% in Asian populations.2–4 In addition, a substantial
fraction of NSCLC patients, who failed previous chemother-
apy, achieve long-term stable disease, leading to disease
control rate exceeding 50% of patients and often associated
with symptomatic improvement and prolonged survival.
Thus, developing a biomarker capable of predicting disease
control rate is equally if not more important than one pre-
dicting only those who have objective response.
Two large placebo controlled randomized studies were
performed with EGFR TKIs as second or third line therapy.1,5
The BR-21 study with erlotinib showed for the first time a
survival benefit for a targeted therapy in NSCLC, whereas the
ISEL study with gefitinib did not demonstrate a significant
survival advantage, although subset analysis in the latter
study did show survival benefit in certain clinical subgroups
(i.e., never smokers and Asians).5,6 In both studies, clinical
effect of EGFR TKIs on survival was seen also in patients
with “unfavorable” clinical characteristics (e.g., males, smok-
ers, and patients with tumors of squamous histology).5,7 Thus,
clinical features seem insufficient for identifying those pa-
tients who would and who would not have survival benefit
from these new agents.
After encouraging results of EGFR TKIs in relapsed
patient categories it was natural to test these drugs in com-
bination with standard first line chemotherapy of advanced
NSCLC. In large prospective randomized studies standard
chemotherapy doublets were given in combination with
EGFR TKIs or placebo, followed by maintenance with active
drugs or placebo.8–11 No benefit from adding EGFR TKIs to
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standard chemotherapy was observed in any of the four
studies, and again clinical characteristics (except for never-
smoking status in the TRIBUTE study) could not identify
subsets of patients who benefited from combination therapy.
Thus, the search for other measures, i.e., biomarkers,
for selection of patients for the EGFR TKIs was mandatory.
EGFR Gene Copy Number
In breast cancer patients, amplification of the HER2
gene detected by fluorescence in situ hybridization (FISH) is
a strong predictive factor for treatment benefit from anti-
HER2 monoclonal antibody, trastuzumab, and recommended
for use in clinical practice.12 EGFR is an important signaling
pathway for lung carcinogenesis13 and was demonstrated to
have a negative prognostic impact.14,15 Thus, it was hypoth-
esized that genomic gain of EGFR is a factor contributing to
growth advantage of NSCLC cells and may be an important
biomarker of sensitivity to EGFR TKIs. Investigators from
the University of Colorado Cancer Center developed an
original scoring system for EGFR gene copy number assessed
by FISH in which tumors were classified into six categories,
based on ascending number of gene copies per cell.16 FISH
negative samples were classified as those with no or low
genomic gain (four copies of the gene per cell in 40% of
cells), and FISH positive samples were defined as tumors
with high gene copy number (four copies of the gene per
cell in 40% of cells) or gene amplification (tight gene
clusters and a ratio of gene/chromosome per cell 2, or 15
gene copies per cell in 10% of the cells). To date, several
major studies have addressed the association between EGFR
gene copy number by FISH and treatment outcome to EGFR
TKIs. All the published studies demonstrated clinically im-
portant treatment benefit in patients with high EGFR gene
copy number with EGFR TKIs versus placebo (Table 1), and
this test is now being validated in prospective clinical studies
in enriched population of NSCLC patients.
Association Between EGFR FISH and Outcome
with EGFR TKIs as Second-Line Therapy
Cappuzzo et al.16 analyzed 102 gefitinib-treated pa-
tients according to EGFR protein expression, phospho-Akt
expression, EGFR gene copy number by FISH, and EGFR
mutations. Patients who were FISH positive had significantly
higher response rate (36% versus 3% in FISH negative
patients), median time-to-progression (9.0 versus 2.5 months,
respectively) and median overall survival (18.7 versus 7.0
months, respectively). The association of FISH positivity and
superior survival was confirmed in multivariate survival anal-
ysis. Evaluation of EGFR gene copy number by FISH was
also performed in tumor samples from 81 participants of the
Southwest Oncology Group 0126 study, which assessed the
role of gefitinib in bronchioloalveolar carcinoma and adeno-
carcinoma with bronchioloalveolar features. In this study,
FISH positive patients had about 50% reduction in the risk of
death as compared with FISH negative patients.17 Data eval-
uating FISH in the ISEL trial are based on a subset of 370
patients, representing the largest evaluation of this biomarker
TABLE 1. Epidermal Growth Factor Receptor Gene Copy Number and Sensitivity to Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
Study
No. of
Patients Drug (dose)
Method of Gene Copy Number
Evaluation (cutpoint)
Proportion
Positive
Response Rates;
Positive vs.
Negative
Survival Hazard
Ratio (95% CI)
Cappuzzo et al.—
retrospective16
102 Gefitinib (250 mg) FISH (high polysomy and gene
amplification)
32.3% 36% vs. 3% 0.44a (0.23–0.82)
Hirsch et al.—SWOG
012617
81 Gefitinib (500 mg) FISH (high polysomy and gene
amplification)
32.0% 26% vs. 11% 0.50a,b (0.25–0.97)
Tsao et al.—BR.2120 125 Erlotinib (150 mg)
vs. placebo
FISH (high polysomy and gene
amplification)
45% 20% vs. 2% 0.44c (0.23–0.82)
Hirsch et al.—ISEL18 370 Gefitinib (250 mg)
vs. placebo
FISH (high polysomy and gene
amplification)
30.8% 16.4% vs. 3% 0.61c (0.36–1.04)
Douillard et al.—
INTEREST21
374 Gefitinib (250 mg)
vs. docetaxel
FISH (high polysomy and gene
amplification)
47% 13.0% vs. 7.4%d 1.09e (0.78–1.51)
Crino et al.—INVITE26 158 Gefitinib (250 mg)
vs. vinorelbine
FISH (high polysomy and gene
amplification)
34% NR 2.88e (1.21–6.83)
Goss et al.—INSTEP25 84 Gefitinib (250 mg)
vs. placebo
FISH (high polysomy and gene
amplification)
38% NR 0.44e (0.17–1.12)
Bell et al.—IDEAL,
INTACT39
90, 453 Gefitinib (250 mg
and 500 mg)
Quantitative PCR (4) 8%, 7% 29% vs. 15%,
56% vs. 53%f
NR, 2.03e (0.67–6.13)
Dziadziuszko et al.—
retrospective38
82 Gefitinib (250 mg) Quantitative PCR (median) 51% 12% vs. 10% 1.04a (0.61–1.76)
Takano—retrospective40 66 Gefitinib (250 mg) Quantitative PCR (3) 44% 72% vs. 38% 0.80a (0.42–1.50)
a Comparison between patients with high vs. low EGFR gene copy number.
b Hazard ratio was recalculated from original publication for consistency in the table. NR, not reported.
c Comparison between EGFR tyrosine kinase inhibitor vs. placebo in patients with high EGFR gene copy number.
d Response rates to gefitinib vs. placebo in patients with high EGFR gene copy number.
e Comparison between EGFR tyrosine kinase inhibitor vs. chemotherapy in patients with high EGFR gene copy number.
f Comparison between patients receiving chemotherapy and gefitinib vs. chemotherapy and placebo.
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in the study of EGFR TKIs in advanced NSCLC, and favor
EGFR gene copy number assessment by FISH as a clinically
useful predictor of treatment benefit from gefitinib versus
placebo.18 The response rate in FISH positive patients was
16% as compared with 3% in FISH negative patients, and the
median survival was almost doubled (8.3 in gefitinib treated
FISH positive patients versus 4.5 months in FISH positive
patients treated with placebo, corresponding to a hazard ratio
[HR] of 0.61). Patients with high EGFR copy number treated
with placebo had slightly inferior survival when compared
with patients with low EGFR gene copy number (4.5 versus
6.2 months, respectively), indicating that increased EGFR
gene copy number by FISH is purely predictive for the benefit
from EGFR TKI and not a prognostic indicator. The lack of
prognostic value of EGFR FISH is also supported by the
results of EGFR gene copy number assessment from surgi-
cally treated NSCLC patients,14 and in NSCLC patients
treated with chemotherapy alone.19 Molecular analysis of
tumor samples from the BR.21 trial was performed using
FISH according to the same criteria, although at a different
institution. Although FISH result could be obtained only in
125 of 221 samples (57%), the subset of FISH positive
patients achieved significant treatment benefit from erlotinib
(20% response rate and a HR of 0.44), whereas this benefit
was modest in FISH negative patients (2% response rate and
a HR of 0.85).20 However, the survival benefit in FISH-
positive patients in this study was not confirmed in the
multivariate analysis that included other biomarkers and clin-
ical features. The authors of this article made no conclusions
regarding the benefit in FISH-positive subset of patients.
Although the ISEL study and the BR-21 studies both
compared EGFR TKI with placebo, randomized studies com-
paring EGFR TKIs with standard chemotherapy in the second
line setting were recently presented. The largest of these
studies was the INTEREST study, which compared gefitinib
with docetaxel as second line treatment.21 The trial included
more than 1400 patients and the results met the primary end
point of noninferiority in the overall survival between the two
arms. EGFR FISH analysis was included as a clinical end
point, however, EGFR FISH results were available only for
26% of overall study population. No difference in outcome
was seen between the FISH-positive and negative patients
between the treatment arms. Based on the previous published
retrospective data it would be expected that the EGFR FISH-
positive patients would perform better with gefitinib as com-
pared with docetaxel. Possible reason for the lack of expected
result in the FISH-positive patients could be that this partic-
ular subset of patients has a poor prognosis without any
systemic therapy, which has been reported by our group,18
and that this poor overall survival would be improved by
chemotherapy per se. Although, the same classification for
EGFR FISH assessment was used in the INTEREST study as
in previous studies technical differences from one laboratory
to another cannot be ruled out on this stage.
Association Between EGFR FISH and Outcome
with EGFR TKIs as First-Line Therapy
EGFR TKIs have been studied in combination with
standard chemotherapy as first line treatment in patients with
advanced NSCLC (outlined in the introduction). Neither of
the four studies could demonstrate any survival advantage of
adding a EGFR TKI to standard chemotherapy. EGFR FISH
analysis has only been performed in the TRIBUTE study and
preliminary data have been presented.22 Although no differ-
ence in the overall population could be demonstrated, the
FISH positive patients had a statistically significant longer
progression-free survival (PFS) compared with the FISH
negative patients. Interestingly, the difference in PFS emerged
after 6 months, which is the time when the patients stopped
chemotherapy and continued with erlotinib alone. Further-
more, a lower response rate was seen in the EGFR FISH
positive group receiving chemotherapy and erlotinib as com-
pared with those receiving chemotherapy and placebo (11.6%
versus 29.8%, p  0.0495). The immediate interpretation of
these results and the raised hypothesis are that during the
treatment with the combination of chemotherapy and EGFR
TKI the agents are acting antagonistic. This hypothesis re-
mains in agreement with observation previously raised by the
investigators from the University of California at Davis. An
EGFR TKI therapy results in a G1 phase cell cycle arrest and
makes the activity of the G2/M phase-specific chemotherapy
suboptimal.23 Based on this hypothesis a pharmacodynamic
separation between the chemotherapy and the EGFR TKI
would be more optimal and this hypothesis is today studied in
prospective clinical trials.24
Data from three phase II clinical studies were recently
presented with EGFR FISH as a predictive marker for ge-
fitinib monotherapy in chemonaïve patients. In the INSTEP
study, 201 chemonaïve NSCLC patients with poor perfor-
mance status (PS 2–3) were randomized to gefitinib versus
placebo.25 Consistently with previous observations, a subset
analysis from patients with available tumor biopsies demon-
strated that FISH positive patients had a HR  0.44 for
survival compared with HR  1.02 in the FISH negative
patient category. In the INVITE study, 196 chemonaïve
NSCLC patients 70 years were randomized to gefitinib
versus vinorelbine. In this trial, the HR for PFS in the FISH
positive patients was 3.13 compared with 0.93 in the FISH
negative category.26 These results, together with the results of
previously discussed INTERST trial,21 indicate that EGFR
FISH does not seem to predict who should be treated with
EGFR TKIs versus who should be treated with chemother-
apy, either in the first or second-line setting (Table 1). More
data on this important issue are urgently needed.
Gefitinib was also tested in a phase II clinical trial
(ONCOBELL study) involving 42 untreated NSCLC patients
with at least two of the following criteria: never-smoking
history, EGFR FISH positivity, or phospho-Akt positivity by
immunohistochemistry.27 Patients who were EGFR FISH
positive had higher response rate (68% versus 9%), longer
median time-to-progression (7.6 versus 2.7 months) and a
trend to longer survival as compared with EGFR FISH
negative patients. Although these results are encouraging,
small patient numbers, multiple selection criteria and lack of
control group do not allow us to assess predictive value of
EGFR FISH based on this trial.
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Association Between EGFR FISH and Outcome
with Anti-EGFR Monoclonal Antibodies
Although most of the studies performed in NSCLC
patients with EGFR antagonists used orally available small-
molecule TKI inhibitors, anti-EGFR monoclonal antibodies
have shown promising results in phase II trials,28–31 but no
predictive marker for outcome and selection of patients has so
far been identified. Several new compounds are currently
actively investigated32 and most data are available for cetux-
imab. The Southwest Oncology Group presented recently
preliminary results from the phase II study 0342,28 in which
the patients were randomized in between chemotherapy and
cetuximab given either concomitantly or sequentially. EGFR
FISH analysis was done in biopsies from the subset of
patients who participated in this study. A doubling of PFS
from 3 to 6 months and of median overall survival from 7 to
15 months was seen for FISH-positive and negative patients,
respectively. Thus, these data indicate that EGFR FISH might
also be strongly associated with outcome after the cetuximab
therapy. Interestingly, the best outcome in the FISH positive
patients was seen in the concurrent arm with a median
survival of 16 months compared with 7 months in the FISH
negative group. Thus, the concurrent therapy with monoclo-
nal antibody and chemotherapy seems to give the expected
synergistic effect in the FISH positive patients, in contrast to
the combination of chemotherapy and EGFR TKIs, where
antagonistic effect is observed.
Two large prospective randomized studies with cetux-
imab in patients with advanced NSCLC have just been
reported. The BMS 099 study comparing taxane/carboplatin
with or without cetuximab was performed in unselected
NSCLC patients and did not meet the primary end point of
superiority in overall survival in the experimental arm.33 The
other study, the FLEX trial (first-line treatment for patients
with EGFR-expressing advanced NSCLC), compared cispla-
tin/vinorelbine with or without cetuximab in EGFR immuno-
histochemistry positive patients. Preliminary announcement
of the results from the latter study showed significantly better
survival by adding cetuximab,34 however, full report from
this trial is awaited. In light of contradictory results of two
studies described above, selection of patients for cetuximab
therapy based on molecular criteria seems to be crucial.
Studies with other anti-EGFR antibodies in NSCLC did not
report on EGFR FISH status.35,36
Methodological Considerations
EGFR gene copy number may be heterogeneous within
different areas of the same tumor and between the primary and
metastatic site, influencing the result of the FISH analysis.37
Clinical significance of tumor heterogeneity with regard to
sensitivity to EGFR TKIs is presently unknown. Other tech-
niques of gene copy number assessment include quantitative
PCR (qPCR) and chromogenic in situ hybridization (CISH). In
the former method, copy number of the gene of interest is
usually compared with that of the housekeeping gene, and
expressed as a relative ratio. Direct comparison of EGFR gene
copy number assessment by FISH and qPCR in 82 advanced
NSCLC patients showed no significant association between
FISH positivity and qPCR results.38 In this study, EGFR gene
copy number by qPCR was not associated with outcome of
gefitinib treated patients. Molecular analysis of IDEAL (phase
II) and INTACT (phase III studies comparing chemotherapy and
gefitinib versus chemotherapy and placebo) demonstrated no
predictive value of EGFR gene amplification by qPCR for
treatment outcome.39 In a study from Japan on 66 gefitinib
treated patients, increased EGFR gene copy number by qPCR
was linked to higher response rate and increased time to pro-
gression, but not overall survival.40 At present, we need more
definitive data to explain why the results of EGFR gene copy
number quantification by FISH and qPCR are different with
respect to its predictive value for EGFR TKI treatment benefit.
Quantification of gene copy number by FISH is possible in
individual tumor cells, whereas qPCR techniques assess gene
copy number in a pool of cells, which may also contain inflam-
matory and stromal components. Tumor microdissection may
help to ensure that the assessment is carried out in areas abun-
dant in tumor cells, but this procedure significantly increases the
assay cost. In qPCR technique, quantification of the reference
gene copy number presents additional challenge because of the
possibility of its deletion or amplification in tumor cells. CISH
technique implements an enzymatic reaction to detect the DNA
probe hybridized to the gene of interest. The main advantage of
this technology is the use of light instead of fluorescent micro-
scope enabling the reader to score the signals in histologic
sections. Data on CISH gene copy number evaluation and
sensitivity to EGFR TKIs are sparse. In a group of 44 NSCLC
patients treated with gefitinib or erlotinib, EGFR gene copy
number by CISH did not associate with response rate.41 A
comparison study between CISH and FISH is currently ongoing.
In summary, retrospective studies have shown a signifi-
cant survival benefit in pretreated NSCLC patients with high
EGFR gene copy number evaluated by FISH, as demonstrated in
several studies involving almost 700 patients. Several prospec-
tive clinical studies with patient selection based on FISH or
combination of FISH and other biomarkers are currently under-
way in the adjuvant, first and second-line setting. The value of
EGFR FISH for the prediction of clinical outcome to EGFR
TKIs compared with first or second-line chemotherapy is not yet
established. Ongoing large prospective adjuvant studies with
EGFR TKIs (i.e., the RADIANT study) in selected patients
based on EGFR expression will further shed light to the use of
EGFR FISH for selection of NSCLC patients to adjuvant ther-
apy. The association of EGFR FISH and outcome of NSCLC
patients treated with chemotherapy and anti-EGFR monoclonal
antibodies is compelling and should be further prospectively
studied.
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